Web Site : http://www.synexus.co.uk/
__________________________________________________________________

Synexus is the largest patient recruitment company in the UK, undertaking clinical trials for pharmaceutical companies and CROs.

AIM Admission document : http://www.synexus.co.uk/pdf/Admission%20to%20trading%20on%20AIM.pdf
__________________________________________________________________

Shares in issue = 21,748,251

Major Shareholders :

IAN SMITH 15.3%

CLOSE VENTURE MANAGEMENT LIMITED 15.2%

ABERDEEN ASSET MANAGERS LIMITED 8.5%

MICHAEL FORT 9.0%

MICHAEL REDMOND 7.4%

MELLON NOMINEES UK LTD 7.07%

BARNARD NOMINEES LTD 7.03%

CANADA LIFE GROUP OF COMPANIES 5.1%
___________________________________________________________________

Pre IPO Research Paper

05/06 PTP 1.4m
05/06 EPS 4.5p

06/07 PTP 2.4m
06/07 EPS 7.7p

This does not allow for any new overseas ventures revenue or earnings.
________________________________________________________________


An extract from www.growthcompany.co.uk 5th Dec 2005 article

Picks for 2006

James Crux
Synexus
Ticker: SNX
Share price: 87.5p
Market cap: 19.0m
52-week high/low: 94.5p/72p

Synexus poised for healthy growth

My tip for the coming year is Synexus, which was recently brought to AIM by Brewin Dolphin with a 3.5 million funding at 65p. It boasts experienced pharmaceuticals entrepreneur Mike Redmond as chairman and specialises in recruiting patients for clinical trials for the global pharmaceutical industry, where clients include such market giants as GlaxoSmithKline and Novartis.

Through its own UK network of investigator sites, the company finds patients, screens them for suitability, and then manages them through the trial before collecting the data and reporting back to clients.

The Synexus model apparently delivers patients faster and at a lower cost than the outdated method of relying on NHS GPs and hospital consultants. Better quality data is another huge plus for its major pharma customers. Large global players are urging Synexus to set up its model in emerging countries like India, Poland and Russia. Profits are forecast to come in at 1.4 million from 10.2 million sales for the year to March. Its my share of the year.

__________________________________________________________________

A few extracts from www.allnewissues.com 18th Oct 2005

Background - Synexus Clinical Research is a provider of clinical trials to the global pharmaceutical industry. The company was formed in April 1998 through the merger of the northern-based general practitioner, Edgebright Partnership, with the southern-based clinical trials division of AEA Technology Plc. In March 2001 the business was subsequently acquired by its management. Synexus is intending to join AIM in early November, and is seeking to raise 3.5 million to repay existing debt, to provide further working capital and to cover the costs of its floatation. For the year ended 31st March 2005, Synexus had turnover of 9.7 million, up from 6.4 million in the year ended March 2004. In the first four months of the current financial year, it has recorded an operating profit of 0.4 million, and due to the long term nature of its contracts, there is a strong visibility of earnings. The company and its nomad, Brewin Dolphin, are in the early stages of marketing, and therefore no indication of the market capitalisation would be given. At allnewissues.com, we believe that a sensible market capitalisation for the company would not be greater than 15 million.


Business Development - At the current stage of Synexus' development a floatation looks sensible. The 3.5 million of equity raised will enable the company to go some way to repaying its existing debt, as well as providing further working capital for growth. Synexus has been experiencing strong organic growth, principally due to the pharmaceutical industry accepting its methodology. Such growth should continue as the company's contracts are of a long term nature. The business model for Synexus is remarkably simple, and the company is building up a strong position within its niche. As the company expands, the service it offers should improve even further. For example, improving its competence in identifying patients through having a larger database of individuals.

The clinical trials market is expanding into India, Poland, Russia and other emerging markets, and Synexus is actively looking to establish operations in these countries. Recently the company signed a partnering agreement with the Indian Clinical Research Institute in Mumbai, India, for the recruitment of patients for clinical trials and is in advanced negotiations with other parties to establish its model in other emerging economies


Investment Conclusion - Given that the prospectus for Synexus is yet to be published, we are not in a suitable position to give a stance on the stock. However the prospects for the company look exciting and it has established a strong position in the sector, having worked with the majority of the 20 largest global pharmaceutical companies, including GlaxoSmithKline, AstraZeneca and Novartis, as well as many of the largest Contract Research Organisations including Quintiles, Icon, PPD and MDS. It is encouraging that Synexus is not going to be reliant upon the UK market, but is looking to expand in the emerging clinical trials market internationally. The company has a good management team, and recorded an operating profit of 0.4 million in the first four months of the current financial year. It will be interesting to see what valuation Synexus will be brought to market at. One To Watch.

http://www.outsourcing-pharma.com/news/ng.asp?n=64752-synexus-irl-patient-recruitment


Indias first patient recruitment SMO up and running

Kirsty Barnes

22/12/2005 - UK-based Synexus Clinical Research has formed the first patient-recruitment site management organisation (SMO) in India to cash in on Indias burgeoning clinical research market.

The company, the largest patient recruitment organisation in Europe, has achieved this through its strategic alliance with IRL, a subsidiary of the Indian Clinical Research Institute, formed earlier this month.
IRL-Synexus will establish a chain of fully owned good clinical practice (GCP)-compliant clinical research centres across India, and the first of which has now been opened in Mumbai. All patients will be recruited through internationally accepted methods and the first patient is expected to be recruited to a trial in the first three months of 2006, said the company.

India's clinical research industry is currently valued at $100 million (83 million) and is almost doubling each year, reflecting the shifting focus of the clinical outsourcing industry to Asia.

India's value in clinical research is compelling for many reasons, including significantly lower costs of conducting trials and a large patient population that are treatment naive and thus ideal candidates for clinical trials.

India possesses tremendous potential to become a preferred location for research and development for the global biotechnology and pharmaceutical sector, Said Dr Ian Smith, medical director of Synexus.

The IRL-Synexus alliance is the first move in the company's new strategy of replicating its UK operations through acquisitions and partnerships across a range of countries important to its clients for running clinical trials.

Report: India to get 10% of global clinical research market

A new report indicates India will capture about 10% of the global clinical research market within the next five years. The Ernest & Young report says about 30% of clinical research will take place outside the U.S. and Western Europe, with much of the work moving to locations that have advantages of language, patient pool, easy recruitment, and the availability of reliable investigators and institutions.

Pharmabiz.com (India) (Dec/29/05)

Looks interesting.

Synexus Clinical Research PLC
31 January 2006

Synexus Clinical Research PLC
Acquisition of Skandynawskie Centrum Medyczne Sp. z o.o.

Acquisition allows Synexus to exploit growing opportunities in Central and
Eastern Europe

Synexus Clinical Research PLC ('Synexus' or 'Company'), the clinical trials
services group, today announces the acquisition of the entire issued share
capital of Skandynawskie Centrum Medyczne Sp. z o.o. ('SCM') for a maximum total consideration of up to 2,250,000, plus the assumption of loans.

This acquisition, the Company's first since joining AIM in November 2005,
follows the Company's stated strategy of expansion through selective
acquisitions, concentrating on Synexus' core activity of patient recruitment for later stage clinical trials, with particular focus on the exploitation of
growing opportunities for clinical trials and patient recruitment in emerging
economies.

Information on SCM

SCM provides clinical trial services for the pharmaceutical industry, managing
patients in clinical trials on behalf of pharmaceutical companies and contract
research organisations. The business is based in Wroclaw, Poland and at present
SCM's main focus is on clinical trials aimed at prevention and treatment of
osteoporosis. In the ten months to 31 October 2005, SCM reported unaudited net
revenues of 425,000 and profit before tax of 130,000. The value of the gross
assets acquired is 335,000 and the value of loans assumed by the Company on
completion is expected to be 245,000.

Benefits of the acquisition

SCM represents an opportunity for the Company to exploit the growing
opportunities for clinical trials and patient recruitment in emerging
Central and Eastern European markets.
The acquisition of SCM, a well-established business operating in the
same area of activity as Synexus, complements the organic growth of the
Company.
SCM contracts with a number of customers in the pharmaceutical industry
who are not currently customers of the Company.
SCM has licences to open further centres in Poland and the opportunity
to open in neighbouring Ukraine.
The acquisition of SCM is expected to be earnings accretive for Synexus
for the first full financial year.

Details of the acquisition

The maximum consideration of 2,250,000 will be satisfied as follows:

850,000 payable on completion by the issue of 1,042,945 new ordinary
shares in Synexus. Application will be made as soon as practicable for these
new ordinary shares to be admitted to trading on AIM.
Up to a further 1,400,000 payable in cash and ordinary shares,
dependent on the level of profit after tax of SCM for the year ending 31
March 2007. In order to earn the maximum level of consideration, SCM would
have to achieve profit after tax of 387,500 in that period.
Up to 150,000 of the loans to be repaid during the earn-out period with
any outstanding balance to be repaid by no later than 31 December 2007.

Commenting on the acquisition, Michael Fort, Chief Executive of Synexus said:

'We are delighted to be able to announce the acquisition of SCM which will
enhance Synexus' business by broadening the service that the Company can offer
to its customers.

The clinical trials market is increasingly expanding into emerging economies and Synexus is actively looking at these markets. We believe that the acquisition of SCM will provide us with a stepping stone to further expansion in Central and Eastern Europe both through organic growth and further acquisitions.

The acquisition of SCM and our partnership recently announced in India represent our intent to implement our strategic aim of developing capability in emerging economies on a fast track basis. This response to market developments will be well received by our customers and will provide the Company with a platform to strengthen sales and profits in the future.'

Note

An exchange rate of 1 : PLN5.6 has been used in this announcement in relation
to the financial information on SCM.

Somethings happening, strong move up today !

Heaven only knows where you pick up these ideas PP. Impressed? You bet.

coeliac1 this one has moved well from 72p, I would say now its fairly well valued, and I think todays rise is coming from a tip magazine. Of course, not complaining over the rise :)

Through to a 104p offer now :)

Fairly flying up today :)

Flying again, I am starting to really enjoy holding this stock, let there be many more like this :) I hope !!

Looking rather undervalued given the proven and potential for Synexus.

Gradually drifting back upwards now.